[HTML][HTML] The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic …
MAM van Hylckama Vlieg, K Nasserinejad… - …, 2023 - thelancet.com
Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
[PDF][PDF] The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review …
MAM van Hylckama Vlieg, K Nasserinejad, C Visser… - 2023 - researchgate.net
Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and …
MAM van Hylckama Vlieg… - …, 2023 - mayoclinic.elsevierpure.com
Background: The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and …
MAM van Hylckama Vlieg, K Nasserinejad… - …, 2023 - wrap.warwick.ac.uk
Background: The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and …
MAM van Hylckama Vlieg… - …, 2023 - researchinformation.amsterdamumc …
Background: The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and …
MAM van Hylckama Vlieg… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
[HTML][HTML] The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic …
MAM van Hylckama Vlieg, K Nasserinejad… - …, 2023 - ncbi.nlm.nih.gov
Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and …
M van Hylckama Vlieg, K Nasserinejad, C Visser… - …, 2023 - europepmc.org
Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
[HTML][HTML] The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic …
MAM van Hylckama Vlieg, K Nasserinejad, C Visser… - eClinicalMedicine, 2023 - Elsevier
Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
[PDF][PDF] The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review …
MAM van Hylckama Vlieg, K Nasserinejad, C Visser… - 2023 - pure.eur.nl
Background The optimal duration of anticoagulation in patients with active cancer and
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …
venous thromboembolism (VTE) is unknown. Current clinical guidelines advocate …